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Abstract
MicroRNAs (miRNAs), 18–24 nt non-coding RNAs, are thought to play important roles in cell proliferation, differentiation,
apoptosis, and development. Recent studies suggest that some of the known microRNAs map to a single genomic locale
within a single polycistronic transcript. But the roles of the cluster remain to be known. In order to understand the role and
mechanism of a cluster of miR-143 and miR-145 in esophageal squamous cell carcinoma (ESCC), the association of mature
miR-143 and miR-145 expression with the risk for esophageal cancer was evaluated in ESCC patients with a case-control
study, and target protein regulated by mature miRNA was analyzed in ESCC cell lines with 39UTR luciferase reporter assay.
The expression levels of miR-143 and miR-145 were determined in 110 pairs of esophageal cancer tissues and adjacent
normal tissues using real-time reverse transcription PCR. The relative expression of miR-143 and miR-145 were statistically
different between cancer tissues and matched controls. The combined expression of miR-143 and miR-145 was significantly
associated with the risk for esophageal cancer. Meanwhile, the reduced expression of two miRNAs in tumor patient was
supposed to have a trend of lymph node metastases. The co-expression pattern of miR-143 and miR-145 was analyzed with
Pearson correlation. It showed a significant correlation between these two miRNAs expression both in tissues and tumor cell
lines. 39UTR luciferase reporter assay indicated that Fascin Homolog 1 (FSCN1) could be co-regulated by miR-143 and miR-
145. The protein level of FSCN1 showed no significant linear correlation with miR-143 and miR-145 expression in ESCC cell
lines with Western blotting analysis. In conclusion, since miR-143 and miR-145 could regulate oncogenic FSCN1 and take
part in the modulation of metastases, the result suggested the combination variable of miR-143 and miR-145 as a potential
biomarker for earlier diagnosis and prognosis of esophageal cancer.
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Introduction
MicroRNAs (miRNAs), 18–24 nt non-coding RNAs, are
thought to play important roles in cell proliferation, differentiation,
apoptosis, and development in recent years [1,2]. They are
involved in endogenous post-transcriptional regulation function
through perfect or imperfect complementary binding to specific
sequences of target mRNAs, which they induce mRNA degrada-
tion or translational inhibition [3]. Many studies have demon-
strated that the loss and gain of function of specific miRNAs may
be key events in the disease process, particularly in the oncogenesis
of cancer [4,5,6,7].
Recent studies suggest that some of the known microRNAs map
to a single genomic locale within a single polycistronic transcript
[8,9,10]. The human mir143/miR-145 cluster contains 2
precursor miRNAs within about 2 kb on chromosome 5
(Figure 1). In this Figure, this cluster is located in the intergenic
region and we predict that this cluster might have a shared
promoter with other genes from UCSC database. The co-
transcription of the two pre-miRNAs implicates that there are
similar expression characteristics between miR-143 and miR-145.
This cluster may play more important role in the cellular function
through cooperative down-regulation of multiple targets compared
with single miRNA function. Several studies explored that miR-
145 or miR-143 played a tumor-suppressive role in various
cancers [11,12,13,14,15,16,17,18]. A large body of evidence
detected by comparative genomic hybridization has established
that 5q is a frequent loss segment in esophageal cancer with a loss
frequency from 18% to 75% [19,20,21,22,23,24,25,26]. Accord-
ingly, the miR-143/miR-145 cluster located in 5q33 might be
deleted or down-regulated in esophageal cancer. We hypothesize
that the aberrant expression of mature miR-145 and miR-143
influence the regulation of target genes and involve in oncogenesis
of esophageal cancer.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33987Moreover, FSCN1 was identified to be one of the targets of
miR-145 [13]. Fascin, a 55 kDa actin-bundling protein encoded
by FSCN1 gene, is an important regulatory element in the
maintenance and stability of parallel bundles of filamentous actin
and plays a central role in the regulation of cell adhesion,
migration and invasion [27,28]. Elevated evidences verified that
fascin epithelial expression was significantly up-regulated in tumor
tissues compared with adjacent benign tissues and the overex-
pression of fascin was associated with aggressive clinical course,
poor prognosis and shorter survival of various tumors including
prostate cancer, breast cancer, gastric cancer, renal cell carcino-
ma, pancreatic cancer, and etc. [29,30,31,32,33,34,35]. The
overexpression of fascin in esophageal squamous cell carcinoma
(ESCC) has been explored recently by several studies. These
findings suggested that fascin was associated with the transforma-
tion and development of ESCC and implicated the potential of
fascin as an early detection biomarker in ESCC [36,37,38,39].
With predicted target genes result from TargetScan software, it is
supposed that fascin can be regulated by miR-145 and miR-143
simultaneously. It implies that miR-143/miR-145 cluster may
regulate the neoplasm process of ESCC through targeting fascin.
In the present study, the association of mature miR-145 and miR-
143 expression with esophageal cancer was determined in 110
pairs of esophageal cancer tissues and adjacent normal tissues, and
target gene FSCN1 regulated by mature miRNA was analyzed in
ESCC cell lines with Western blotting and 39UTR luciferase
reporter assay.
Results
Demographic characteristics
There are 110 patients with newly diagnosed, untreated
esophageal squamous carcinoma recruited in the present study.
The average age of the patients was 61.6367.74 years. The ratio
of male to female was 2.24. Of these patients diagnosed with
pathological reports, 79 (71.8%) of 110 were diagnosed as well
differentiated (I+II), 31 (28.2%) as poorly differentiated. Lymph
node metastases were observed in 40 of 110 patients (36.4%).
Differential expression of miR-143 and miR-145 in ESCC
tissues and tissues adjacent to tumors
Using the quantitative RT-PCR technique, the expression of
miR-143 and miR-145 was determined in tumor tissues and tissues
adjacent to tumors from cancer patients. Normalization to
reference gene is essential for relative quantification of miRNA
expression using real time PCR assay. U6 small nuclear RNA is
highly conserved across species and the function of U6 snRNA has
remained crucial to organism viability. Therefore, U6 snRNA
shows relatively stable expression level in different tissues and cells
[40]. Moreover, it doesn’t participate in regulation network of
microRNAs, which indicates that it is independent to microRNAs
as an internal control. U6 snRNA has a comparable size with
microRNAs, which guarantees the similar reverse-transcription
efficiency between U6 snRNA and microRNAs. In sum, U6 fits
the criterion of reference gene for real time RT-PCR and was used
as an internal control in this study. With normalization of U6, the
relative expression levels of miR-143 and miR-145 are presented
in Figure 2. As relative expression data displayed the log-normal
distribution, logarithmic transformation were performed in these
data. As shown in Table 1, the relative expression of both two
miRNAs showed statistical differences between cancer tissues and
controls. Conditional logistic regression analysis revealed that
significantly increased risk for esophageal cancer was associated
with reduced expression of miR-143 and miR-145 (OR=4.292,
3.367 respectively).
The associations of miR-143 and miR-145 with clinicopatho-
logical features were carried out with ANOVA or GLM analysis.
There was no significant difference of miRNA expression
according to age (p=0.059, 0.240), gender (p=0.663, 0.095),
family history of cancer (P=0.643, 0.653), tumor location
(p=0.514, 0.841), or differentiation (p=0.099, 0.069). But the
relative expression levels of miR-143 and miR-145 were different
in the patients with Lymph node metastasis (p=0.028, 0.017,
Table 2 and Table 3).
T-test analysis was performed to determine the association
between environmental factors and miRNA expression. As shown
in Table 2 and Table 3, the result revealed that the expression
level of miR-145 was significantly decreased in heavy smoking
patients compared with non-smokers or occasional smokers
(P=0.013), while the expression level of miR-143 was significantly
decreased in heavy drinking patients compared with non-drinkers
or occasional drinkers (P=0.043).
Co-expression analysis of miR-143 and miR-145 cluster
The correlation of miR-143 and miR-145 was analyzed using
Pearson correlation. With the log-transformed relative expression
data from tumor tissues and tissues adjacent to tumor, Pearson
correlation coefficient between miR-143 and miR-145 was
determined as 0.322 (P=0.0006) and 0.289 (P=0.0022), respec-
tively. When combined the expression datum of two groups into
Figure 1. Schematic representations of miR-143 and miR-145 cluster in Chromosome. The human precursor mir143 and precursor miR-
145 are located at the same intergenic region within about 2 kb on chromosome 5, which can be suggested to be a cluster. The mir143/miR-145
cluster might have a shared promoter with other genes from UCSC database.
doi:10.1371/journal.pone.0033987.g001
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33987Figure 2. Differential expression of miR-143 and miR-145 in ESCC tissues and tissues adjacent to tumors. A represents the difference of
miR-143 expression in each pair of tumor tissue (T) and adjacent normal tissue (N) from 110 ESCC patients. B represents the difference of miR-145
expression in each pair of tumor tissue (T) and adjacent normal tissue (N) from 110 ESCC patients.
doi:10.1371/journal.pone.0033987.g002
Table 1. Downregulation of miR-143 and miR-145 expression associated with a high risk of ESCC.
Group Size
Relative expression level
(95%CL)
Differential expression
level P value (t test) OR (95%CL)
miR-143
Tumor tissues 110 21.943 (22.439, 21.449) 23.037 (23.538, 22.536) ,0.0001 0.233 (0.124, 0.437)
Tissues adjacent to tumor 110 1.094 (0.615, 1.573)
miR-145
Tumor tissues 110 0.0587 (20.364, 0.482) 23.735 (24.240, 23.229) ,0.0001 0.297 (0.176, 0.500)
Tissues adjacent to tumor 110 3.793 (3.367, 4.220)
doi:10.1371/journal.pone.0033987.t001
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between miR-143 and miR-145 as Figure 3 (R=0.528,
P,0.0001). It indicated that miR-143 and miR-145 were co-
expressed in tumor tissues and tissues adjacent to tumor.
Logistic regression analysis was restarted according to the new
independent variable defined as a combination value of miR-143
and miR-145. The linear regression equation of miR-143 and miR-
145 was determined as follows. Y(miR-143)=1.938X(miR-145)-
4.157. And the combination value of miR-143 and miR-145 was
defined as Y(combination)=2.938X(miR-145). The result showed
that significantly increased risk for esophageal cancer was associated
with reduced expression of combination variable, which implied
that the combination variable of miR-143 and miR-145 might be
potential biomarker for earlier diagnosis of esophageal cancer.
Expression of miR-143 and miR-145 cluster in ESCC cell
lines
The relative expression of miR-143 and miR-145 were
determined in five ESCC cell lines normalized by U6 (Figure 4).
EC9706 showed the lowest expression of miR-143 and miR-145,
while KYSE510 had the highest expression. Since the expression
of miR-145 was almost undetectable in EC9706, the correlation
analysis between miR-143 and miR-145 was performed in ESCC
cell lines except for EC9706. A significant positive correlation was
found with 0.88 of R value. The result suggested a co-expression
pattern between miR-143 and miR-145.
Validation of FSCN1 as a target gene co-regulated by
miR-143 and miR-145 using Luciferase Reporter Assay
Fascin homolog1 (FSCN1) was predicted to be regulated by
miR-143 and miR-145 simultaneously with a miRNA target
prediction tool (TargetScan Release 6.0). To confirm this
predicted result, 39UTR of FSCN1 was cloned to construct
luciferase reporter vector. Figure 5 showed the luciferase signal
results from co-transfection of 39UTR constructs from FSCN1
with miR-143 mimic, miR-145 mimic, miR-143 and miR-145
mimic mixture or negative control. ANOVA analysis based on
factorial experiment design indicated that both miR-143 and miR-
145 inhibited 39UTR expression of FSCN1 significantly
(P,0.0001). The miR-143 showed 2-fold higher inhibition
efficiency than miR-145. Co-transfection of miR-143 and miR-
145 showed a synergistic effect on suppressing the expression of
FSCN1 (P,0.0001).
Association of FSCN1 with miR-143/miR-145 cluster using
Western Blotting assay
Since Fascin homolog1 (FSCN1) was confirmed to be regulated
by miR-145 and miR-143 simultaneously with 39UTR luciferase
reporter assay, the protein levels of FSCN1 in five ESCC cell lines
were determined by Western Blotting to explore the actual
association between FSCN1 protein and miR-143/miR-145
cluster. As shown in Figure 6, normalized by b-actin, FSCN1
had a highest level in KYSE-510 and a lowest level in EC109.
Table 2. The associations of miR-143 expression with
demographic and clinical characteristics.
Group Size miR-143 (Mean, 95%CL) P value
Age
,60 46 23.601 (24.413, 22.789) 0.059
$60 64 22.632 (23.266, 21.999)
Gender
Male 76 22.963 (23.582, 22.344) 0.663
Female 34 23.203 (24.093, 22.313)
Family history of cancer
No 94 23.086 (23.641, 22.531) 0.643
Yes 16 22.751 (23.992, 21.510)
Tumor location
Upper part of esophagus 6 23.587 (26.486, 20.687) 0.514
Middle part of esophagus 93 23.098 (23.653, 22.543)
Lower part of esophagus 11 22.222 (23.739, 20.704)
Differentiation
I and II 79 22.776 (23.344, 22.208) 0.099
III 31 23.704 (24.754, 22.654)
Lymph node metastasis
No 70 22.618 (23.215, 22.020) 0.028
Yes 40 23.772 (24.658, 22.885)
Smoking index
,400 47 23.054 (23.761, 22.347) 0.940
$400 63 23.015 (23.736, 22.294)
Alcohol use
None or occasional 62 22.458 (23.247, 21.670) 0.043
Often 48 23.486 (24.129, 22.842)
doi:10.1371/journal.pone.0033987.t002
Table 3. The associations of miR-145 expression with
demographic and clinical characteristics.
Group Size miR-145 (Mean, 95%CL) P value
Age
,60 46 24.089 (24.896, 23.283) 0.240
$60 64 23.480 (24.138, 22.822)
Gender
Male 76 23.450 (24.054, 22.846) 0.095
Female 34 24.372 (25.305, 23.438)
Family history of cancer
No 94 23.782 (24.347, 23.218) 0.653
Yes 16 23.455 (24.628, 22.283)
Tumor location
Upper part of esophagus 6 23.847 (26.165, 21.529) 0.841
Middle part of esophagus 93 23.781 (24.318, 23.244)
Lower part of esophagus 11 23.283 (25.682, 20.884)
Differentiation
I and II 79 23.445 (24.044, 22.846) 0.069
III 31 24.474 (25.417, 23.531)
Lymph node metastasis
No 70 23.277 (23.833, 22.721) 0.017
Yes 40 24.536 (25.512, 23.559)
Smoking index
,400 47 23.189 (23.831, 22.547) 0.013
$400 63 24.466 (25.255, 23.677)
Alcohol use
None or occasional 62 23.686 (24.504, 22.867) 0.866
Often 48 23.773 (24.428, 23.118)
doi:10.1371/journal.pone.0033987.t003
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showed no statistical significance.
Discussion
The role of miRNA in tumorigenesis has been extensively
studied in recent years. A early evidence showed that miRNAs
were commonly located in fragile sites on chromosomes,
preferential sites of translation, deletion and amplification that
are often altered in cancers [41]. 5q, located with miR-143/miR-
145 cluster, was found to be frequently lost in esophageal cancer
detected by comparative genomic hybridization [23]. Hu et al
identified 5q with very high frequency (./=75%) loss of
heterozygosity from a genomewide scan of esophageal squa-
mous-cell carcinoma in a high-risk Chinese population [19].
Montesano et al and Moskaluk et al all explored 5q was frequent
target of deletion in esophageal cancer and may harbor novel
tumor suppressor genes [21,22]. The cluster of miR-143 and miR-
145 is predicted within about 2 kb on chromosome 5 plus chain by
miRGen clusters tool (http://www.diana.pcbi.upenn.edu/cgi-
bin/miRGen/v3/Cluster.cgi). And two alternative promoters are
found to be located within 24 kb upstream of miR143–miR145
cluster, which suggests that this cluster may be co-transcribed and
play more important role in biological function than other single
miRNAs. Several researches showed that the expression levels of
miR-143 and miR-145 were downregulated in multiple tumor
tissues including lung cancer, gastric cancer, breast cancer,
colorectal cancer and etc. when compared with adjacent normal
Figure 4. Relative expression of miR-143 and miR-145 in ESCC cell lines. Red bar and blue bar represent the relative expression of miR-143
and miR-145 normalized by U6 in five ESCC cell lines respectively. The correlation analysis suggested a co-expression pattern between miR-143 and
miR-145.
doi:10.1371/journal.pone.0033987.g004
Figure 3. Scatter plot of miR-143 and miR-145 expression in ESCC patients. Relative expression of miR-143 and miR-145 normalized by U6
were evaluated with Pearson correlation analysis. Square represents samples from tumor tissues and triangle represents samples from normal tissues
adjacent to tumor. The mixed sample set showed a significantly positive correlation between miR-143 and miR-145 expression.
doi:10.1371/journal.pone.0033987.g003
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are co-transcribed and what function this cluster has remains to be
understood.
In the present study, we found that the relative expression of
both two miRNAs showed statistical differences between cancer
tissues and controls. Moreover, they showed a significant
correlation between these two miRNAs expression both in tumor
tissues and tumor cell lines. It suggested that miR-143 and miR-
145 were co-expressed descendingly in esophageal cancer. The
combined expression of miR-143 and miR-145 was significantly
associated with the risk for esophageal cancer. Meanwhile, the
reduced expression of two miRNAs in tumor patient was supposed
to have a trend of lymph node metastases.
In order to understand the process of miR-143 and miR-145
cluster affecting the development and metastases of esophageal
cancer, we searched for the target gene regulated by miR-143 and
miR-145simultaneously.FSCN1waspredictedtobeco-targeted by
miR-143 and miR-145 with TargetScan and the co-regulation
relationship of miR143 and miR-145 then was confirmed using
39UTR luciferase reporter assay. Fascin can organize filamentous
actin into bundles and plays a role in the formation of microspikes,
membrane ruffles, and stress fibers. It induces the formation of
membrane protrusions, and promotes cell motility and migration
(http://www.uniprot.org/uniprot/Q16658#section_comments).
The overexpression of fascin in esophageal squamous cell
carcinoma (ESCC) has been described [36]. Using RNA interfer-
ence (RNAi), fascin was stably silenced, which resulted in a
suppression of cell invasiveness [38]. FSCN1 was recently identified
to be a direct target gene regulated by miR-145 with luciferase
reporter assay [13]. And our result also indicated that 39UTR of
FSCN1 could be co-regulated by miR-143 and miR-145. With
these researches, we suggested that miR-143 and miR-145 could
control oncogenic FSCN1 and take part in the modulation of
metastases. Even though our present result showed no significant
correlation between miR-143 and miR-145 co-expression and
protein level of FSCN1, it was supposed that FSCN1 could be
regulated by multiple miRNAs and may not reveal linear
correlation with miR-143 and miR-145 co-expression.
In conclusion, miR-143 and miR-145 were suggested to be co-
expressed descendingly in esophageal cancer in the present study.
The combined expression of two miRNAs in tumor patient
showed a negative association with lymph node metastases. The
cluster of miR-143 and miR-145 should take part in the
modulation of metastases through targeting oncogenic FSCN1.
The result suggested the combination variable of miR-143 and
miR-145 as a potential biomarker for earlier diagnosis and
prognosis of esophageal cancer.
Materials and Methods
Study Subjects and Ethics Statement
110 patients with newly diagnosed, untreated esophageal cancer
were recruited in the present study. All cases were from Huaian
county of Jiangsu province, China. Patients were newly diagnosed
with histologically confirmed primary cancer and previously
untreated (no radiotherapy or chemotherapy) ESCC from
October 2008 to December 2010. During the period of
recruitment, each subject was scheduled for an interview after
informed consent was written, and a structured questionnaire was
administered by the interviewer to collect information about
demographic data and risk factors such as smoking status, alcohol
use etc.. Esophageal cancer tissues and tissues adjacent to the
tumors were macro-dissected from each subject during operation.
In order to ensure a high proportion of tumor cells when collecting
tumor tissue, the site and range of tumor were determined and
0.5 m
2 of tumor tissue outward from the center was captured only
Figure 5. Luciferase reporter assay for 39UTR of FSCN1 regulated by miR-143 and miR-145. Bar represents the RLU of negative control
(NC), miR-145 mimic, miR-143 mimic, or miR-143 and miR-145 mimic mixture co-transfected with 39UTR constructs of FSCN1. Asterisk (*) shows the
statistically significant difference between negative control treatment and miRNA mimic treatment with ANOVA analysis based on factorial
experiment design. Fold change shows the ratio of RLU from negative control treatment divided by RLU from miRNA mimic treatment.
doi:10.1371/journal.pone.0033987.g005
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larger. For normal epithelial cells collection, 0.5 m
2 of esophagus
was dissected further than 5 centimeters from the tumor edge and
then muscle layer and connective tissue were removed thoroughly
to get the high purity of esophageal epithelia. Within half an hour
after tissues dissected, the samples were stored into RNAlocker
reagent for miR-143 and miR-145 expression analysis using real
time RT-PCR assay. The population study was approved by the
institutional review board named as ‘‘IRB of Southeast University
Affiliated Zhongda Hospital’’ in Nanjing, China. IRB of Southeast
University Affiliated Zhongda Hospital approved the design of
esophageal cancer study including tissue samples collection.
Cell lines and culture
All human ESCC cell lines used in the present study were
established cell lines as follows. EC9706 and EC109 were
purchased from Shanghai Tiancheng Technology Co., Ltd.
CaEs-17 were purchased from Nanjing KeyGen Biotech Co.,
Ltd.. KYSE150 and KYSE510 were purchased from Cell Center
of Shanghai Institute of Life Science, Chinese Academy of
Science. Cell lines were cultured in RPMI1640 medium (Invitro-
gen) supplemented with 10% heat-inactivated fetal bovine serum
(Invitrogen) and 1% penicillin/streptomycin (Sigma-Aldrich).
Cells were incubated in a humidified incubator at 37uC and 5%
CO2. The trypsinized cells were harvested for miRNAs expression
and fascin analysis using real time RT-PCR and Western blotting
respectively.
Isolation of Total RNA and Total Proteins
Esophageal tissues were homogenized in 1 ml of TRIZOL
reagent per 30–50 mg of tissue. Cell pellets were homogenized in
1 ml of TRIZOL reagent per 10
6 cells. Total RNA was isolated
from homogenate according to the manufacturer’s instructions,
extracted with chloroform, precipitated with isopropyl alcohol,
Figure 6. Association of FSCN1 with miR-143/miR-145 cluster. A represents the protein level of FSCN1 normalized by b-actin in five ESCC cell
lines with different miR-143 and miR-145 expression level using Western Blotting assay. B represents the scatter plots of miR-143 (square) and miR-
145 (diamond) expression correlated with FSCN1 protein in ESCC cell lines.
doi:10.1371/journal.pone.0033987.g006
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concentrations of RNA were determined spectrophotometrically
by monitoring UV absorbance at 260 nm. Purity was assessed by
the absorbance ratio 260/280 nm.
Total cell lysates were prepared in RIPA buffer [50 mmol/L
TrisHCl, pH 8.0, 150 mmol/L NaCl, 1% (vol/vol) Nonidet P-40,
0.5% (wt/vol) sodium desoxycholate, 0.1% (wt/vol) SDS]
containing the complete protease inhibitor cocktail. Protein
concentration was determined using the Bio-Rad protein assay
(Bio-Rad) with BSA as standards.
Quantitative Reverse Transcription PCR
Quantitative reverse transcription PCR analysis of miRNA
expression was carried out using a 7300 Real Time PCR System
(Applied Biosystems). U6 small nuclear RNA was used as an
internal control to normalize RNA input. Briefly, 10 ml reverse
transcription (RT) reaction mixture contained 0.5 mg of total
RNA, 5 nM of miRNA-specific stem-loop RT primer, 500 mMo f
dNTP mixture, 2 mlo f5 6RT buffer, 10 U of Ribonuclease
Inhibitor (Sigma), 100 U of MMLV (Promega), and RNase-free
water to final volume. The RT reaction was performed as follows:
16uC for 30 minutes, followed by 42uC for 60 minutes, heated to
85uC for 5 minutes and then stored at 220uC. Specific reverse
transcription primers for miR-143 and miR-145 cDNA synthesis
were 59- GTC GTA TCC AGT GCG TGT CGT GGA GTC
GGC AAT TGC ACT GGA TAC GAC AGG GAT -39 and 59-
GTC GTA TCC AGT GCG TGT CGT GGA GTC GGC AAT
TGC ACT GGA TAC GAC GAG CT- 39 respectively. Specific
reverse transcription primer for U6 was 59- GTC GTA TCC
AGT GCA GGG TCC GAG GTG CAC TGG ATA CGA CAA
AAT ATG GAA C -39.
The real-time PCR was carried out in 96-well plates (Axygen)
with a final volume of 20 ml using SYBR Green I dye. The PCR
reaction components were 1 ml of cDNA synthesized as above,
10 mlo f2 6SYBR Green PCR Master Mix, and 0.6 mM of each
pair of oligonucleotide primers. Thermal cycling conditions were
95uC for 5 minutes, followed by 40 cycles of 95uC for 15 s, 60uC
for 60 s. A dissociation curve analysis was added after the final
PCR cycle to evaluate the presence of nonspecific PCR products
and primer dimers. Specific primers for miR-145 cDNA
amplification were 59- TCG GTC CAG TTT TCC CAG -39
(sense) and 59- AGT GCG TGT CGT GGA GTC -39 (antisense)
with the product size of 65 bp. Specific primers for miR-143
cDNA amplification were 59- AGC GTG TGT CGT GGA GTC
-39 (sense) and 59- TCG TGA GAT GAA GCA CTG TAG -39
(antisense) with the product size of 63 bp. Primer sequences for U6
were 59- TGC GGG TGC TCG CTT CGG CAG C -39 (sense)
and 59- CCA GTG CAG GGT CCG AGG T -39 (antisense) with
the product size of 144 bp. The amount of template cDNA was
expressed by a threshold cycle (Ct) that was determined by the
amplification curve (exponential phase). The parameter Ct was
defined as the fractional cycle number at which the fluorescence
caused by the binding of SYBR Green dye to double-stranded (ds)
DNA reaches detection threshold. The miRNA levels were
compared between subjects by a comparative Ct method with
separate tubes, as described elsewhere [45]. Briefly, the individual
level of initial target cDNA was expressed as the difference in Ct
between the target and an internal control U6 (DCt).
Luciferase reporter assay
TargetScan release 6.0 was used to predict co-regulated target
genes of miR-143 and miR-145. For confirmation of direct target
binding, the 39UTR of FSCN1 identified by TargetScan was
cloned into a 39UTR_vector (GeneCopoeia Genomics). EC9706
cells were seed into a 96-well plate with a concentration of 10
thousand cells each well in 100 ml total volume and incubated for
24 hours. Cells were then co-transfected with miR-143 mimic,
miR-145 mimic, miR-143 and miR-145 mimic mixture or
negative control and 39UTR_vector. 100 ng of 39UTR_vector
was mixed with 1.5 pmol of miRNA mimic or negative control in
10 ml of OPTI-MEM. 0.25 ml of lipofectamine2000 was diluted
into 10 ml of OPTI-MEM and added into the former mixture after
incubated for 5 minutes. When incubated for another 20 minutes,
20 ml of transfection mixture and 80 ml of antibiotics-free
RPMI1640 media were added into the 96-well plate and
incubated at 37uC and 5% CO2 for 24 hours. The substrate
solution was used for luciferase assay. After incubation of
30 minutes, the signal from each well was read with Mithras LB
940 (Berthold Technologies). Luciferase signal ratio for specific
miRNA over negative control was calculated for each construct.
Western Blotting of FSCN1
The protein levels of FSCN1 were determined in the ESCC cell
lines by western blotting. Twenty mg of the isolated total proteins
were mixed with 26loading buffer and boiled for 5 minutes. SDS-
PAGE was performed with 12% separation gel concentration and
5% spacer gel concentration. b-actin (45 KD) and FSCN1
(55 KD) were transferred PVDF membrane at 250 mA for
1.5 hour. Blocking was performed with 5% nonfat milk for 2 hour
at room temperature. Primary mouse anti-human b-actin IgG and
rabbit anti-human FSCN1 IgG titers were optimized at 1:5000
and 1:1000 respectively, and incubated with the membrane for
1.5 hour at room temperature. After washing with PBS buffer, the
membrane was incubated with the secondary antibody (dilution
1:5000) for 1.5 hour at room temperature. Identical substrates
were used in each assay for enhanced chemiluminescence
detection (Pierce) according to the manufacturer’s protocol.
Statistical Analysis
The prediction of microRNA targets was carried out through
TargetScan (release 6.0, http://www.targetscan.org/) by search-
ing for the presence of conserved and poorly conserved 8 mer and
7 mer sites that match the seed region of microRNA [46].
Analysis of variance (ANOVA), Chi-square test, and logistic
regression analysis were used to determine the statistical
differences between tumor tissues and tissues adjacent to the
tumors at a significance level of 5%. The correlation coefficients of
miR-143 and miR-145 were calculated using the Pearson
correlation. The relationships between miRNAs expression and
FSCN1 expression were analyzed using the Pearson correlation.
All statistical analysis mentioned above were performed using SAS
software (Version 9.0).
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